Related references
Note: Only part of the references are listed.Prognostic significance of epidermal growth factor receptor overexpression in pancreas cancer and nodal metastasis
Marcos Vinicius Perini et al.
ANZ JOURNAL OF SURGERY (2015)
Relationship between EGFR Over-expression and Clinicopathologic Characteristics in Squamous Cell Carcinoma of the Esophagus: A Meta-analysis
Jun Wang et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models
Gaeelle Thomas et al.
ONCOTARGET (2014)
The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
Hisato Kawakami et al.
ONCOTARGET (2014)
HER2 Gene Amplification and Protein Expression in Pancreatic Ductal Adenocarcinomas
Klaus Aumayr et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2014)
Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Prognostic value of epidermal growth factor receptor in patients with gastric cancer: A meta-analysis
Liu Hong et al.
GENE (2013)
HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis
Alberto Ocana et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma
Matias E. Valsecchi et al.
CANCER (2012)
Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
Charlotte F. McDonagh et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer
R. A. Smith et al.
BRITISH JOURNAL OF CANCER (2011)
Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome
Maria D. Begnami et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
C. Gridelli et al.
LUNG CANCER (2011)
HER3 Overexpression as an Independent Indicator of Poor Prognosis for Patients with Curatively Resected Pancreatic Cancer
Toshiki Hirakawa et al.
ONCOLOGY (2011)
Role of Epidermal Growth Factor Receptor Expression on Patient Survival in Pancreatic Cancer: A Meta-Analysis
Guopei Luo et al.
PANCREATOLOGY (2011)
Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status
R. L. Rego et al.
BRITISH JOURNAL OF CANCER (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma
Matthew H. G. Katz et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
HER2 overexpression correlates with survival after curative resection of pancreatic cancer
Masahiro Komoto et al.
CANCER SCIENCE (2009)
HER-family gene amplification and expression in resected pancreatic cancer
E. A. te Velde et al.
EJSO (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival
SM Wiseman et al.
CANCER (2005)
Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast
NLP Barnes et al.
CLINICAL CANCER RESEARCH (2005)
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma
DM Abd El-Rehim et al.
BRITISH JOURNAL OF CANCER (2004)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Resected adenocarcinoma of the pancreas - 616 patients: Results, outcomes, and prognostic indicators
TA Sohn et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2000)
The ErbB signaling network: receptor heterodimerization in development and cancer
MA Olayioye et al.
EMBO JOURNAL (2000)
Share Paper
